Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 23;13(9):907.
doi: 10.3390/antibiotics13090907.

Comparing the Outcomes of Cefoperazone/Sulbactam-Based and Non-Cefoperazone/Sulbactam-Based Therapeutic Regimens in Patients with Multiresistant Acinetobacter baumannii Infections-A Meta-Analysis

Chienhsiu Huang  1 , Lichen Lin  2 , Sufang Kuo  2
Affiliations
Review

Comparing the Outcomes of Cefoperazone/Sulbactam-Based and Non-Cefoperazone/Sulbactam-Based Therapeutic Regimens in Patients with Multiresistant Acinetobacter baumannii Infections-A Meta-Analysis

Chienhsiu Huang et al. Antibiotics (Basel). .

Abstract

The addition of sulbactam restores the complete range of cefoperazone activity against bacteria and extends its spectrum of action to include the Acinetobacter species. The effectiveness of cefoperazone/sulbactam against multiresistant Acinetobacter baumannii has not been investigated. The purpose of the current meta-analysis was to compare the efficacy of cefoperazone/sulbactam-based therapeutic regimens and non-cefoperazone/sulbactam-based therapeutic regimens in the treatment of multiresistant Acinetobacter baumannii infections. The current meta-analysis of 10 retrospective studies provides evidence that cefoperazone/sulbactam-based therapeutic regimens are superior to non-cefoperazone/sulbactam-based therapeutic regimens in terms of 30-day mortality and clinical improvement in patients with multiresistant Acinetobacter baumannii infections. The risk of mortality was reduced by 38% among multiresistant Acinetobacter baumannii infections in patients who received cefoperazone/sulbactam-based therapeutic regimens. The cefoperazone/sulbactam-based combination therapy was superior to the cefoperazone/sulbactam monotherapy in terms of 30-day mortality when both therapeutic regimens were compared to the tigecycline monotherapy in patients with multiresistant Acinetobacter baumannii infections.

Keywords: Acinetobacter baumannii; cefoperazone; mortality; multiresistant; sulbactam.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Flow diagram of the study selection process.
Figure 2
Figure 2
The 30-day mortality rate between patients treated with cefoperazone/sulbactam-based therapeutic regimens and those treated with non-cefoperazone/sulbactam-based therapeutic regimens. (Inverted funnel plots revealed a symmetric relationship) [9,17,18,20,21,22].
Figure 3
Figure 3
The clinical improvement between patients treated with cefoperazone/sulbactam-based therapeutic regimens and those treated with non-cefoperazone/sulbactam-based therapeutic regimens. (Inverted funnel plots revealed a symmetric relationship) [14,15,16,19].
Figure 4
Figure 4
The 30-day mortality rate between patients treated with cefoperazone/sulbactam monotherapy and those treated with tigecycline monotherapy. (Inverted funnel plots revealed a symmetric relationship) [17,20,22].
Figure 4
Figure 4
The 30-day mortality rate between patients treated with cefoperazone/sulbactam monotherapy and those treated with tigecycline monotherapy. (Inverted funnel plots revealed a symmetric relationship) [17,20,22].
Figure 5
Figure 5
The 30-day mortality rate between patients treated with cefoperazone/sulbactam-based combination therapy and those treated with tigecycline monotherapy. (Inverted funnel plots revealed a symmetric relationship) [17,20,22].
Figure 5
Figure 5
The 30-day mortality rate between patients treated with cefoperazone/sulbactam-based combination therapy and those treated with tigecycline monotherapy. (Inverted funnel plots revealed a symmetric relationship) [17,20,22].
See this image and copyright information in PMC

References

    1. Peleg A.Y., Seifert H., Paterson D.L. Acinetobacter baumannii: Emergence of a successful pathogen. Clin. Microbiol. Rev. 2008;21:538–582. doi: 10.1128/CMR.00058-07. - DOI - PMC - PubMed
    1. Eliopoulos G.M., Maragakis L.L., Perl T.M. Acinetobacter baumannii: Epidemiology, antimicrobial resistance, and treatment options. Clin. Infect. Dis. 2008;46:1254–1263. doi: 10.1086/529198. - DOI - PubMed
    1. Gales A.C., Castanheira M., Jones R.N., Sader H.S. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: Results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008–2010) Diagn. Microbiol. Infect. Dis. 2012;73:354–360. doi: 10.1016/j.diagmicrobio.2012.04.007. - DOI - PubMed
    1. Nutman A., Glick R., Temkin E., Hoshen M., Edgar R., Braun T., Carmeli Y. A case-control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteraemia. Clin. Microbiol. Infect. 2014;20:O1028–O1034. doi: 10.1111/1469-0691.12716. - DOI - PubMed
    1. Hu F.P., Guo Y., Zhu D.M., Wang F., Jiang X.F., Xu Y.C., Zhang X.J., Zhang C.X., Ji P., Xie Y., et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005–2014. Clin. Microbiol. Infect. 2016;22((Suppl. S1)):S9–S14. doi: 10.1016/j.cmi.2016.01.001. - DOI - PubMed

LinkOut - more resources